CClinicalTrials.gg
RecruitingNCT07591207Updated Jun 16, 2026

The Efficacy and Safety of Loxoprofen Sodium Patch in Relieving Postoperative Pain After Laparoscopic Surgery

An interventional study of Loxoprofen Sodium Patch on the contralateral side and Loxoprofen Sodium Patch on the incision site in Loxoprofen Sodium Patch, Local Incision and Laparoscopic Cholecystectomy, sponsored by Beijing Tiantan Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

Studies have shown that up to 80% of patients experience postoperative pain following laparoscopic surgery due to inflammation caused by surgical incisions and surrounding tissues, necessitating pharmacological relief. Inflammatory mediators released from the soft tissues around laparoscopic incisions not only significantly alters the chemical microenvironment at the peripheral terminals of nociceptors, directly inducing pain, but also sensitizes afferent fibers, contributing to peripheral sensitization.

The investigators conducted a multicenter, prospective, randomized controlled clinical study to explore the use of Loxoprofen Sodium Patch for preoperative local incision analgesia in laparoscopic surgery patients. The investigators aim to observe whether this method can effectively alleviate postoperative incision pain, reduce the dosage of postoperative analgesics and the side effects caused using postoperative analgesics, improve patient satisfaction, and provide new ideas for postoperative analgesia in laparoscopic surgery patients, promoting rapid recovery after laparoscopic surgery.

02

Conditions studied

  • Loxoprofen Sodium Patch
  • Local Incision
  • Laparoscopic Cholecystectomy
  • Appendectomy, Laparoscopic
  • Hernia Repair
03

In context

Lead sponsor

Beijing Tiantan Hospital is the lead sponsor of 465 studies on the registry; 282 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients scheduled for elective Laparoscopic Surgery for laparoscopic cholecystectomy, appendectomy, or hernia repair under general anesthesia;
  2. Ages 18 to 64 years old
  3. American Society of Anesthesiologists (ASA) physical status of I-III
  4. Patients must be able to understand the nature and potential personal consequences of the clinical trial and cooperate with follow-up investigations
  5. signing of the informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. History of chronic pain syndrome of any cause and mental illness
  2. Excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks or 3 days per week for more than 1 month), use of drugs with confirmed or suspected sedative or analgesic effects, or use of any painkiller within 24 h before surgery.
  3. History of hypertension (Grade 3, extremely high risk)
  4. Pregnancy or breastfeeding.
  5. Extreme body mass index (BMI) (\< 15 or > 35).
  6. Participation in another interventional trial that interferes with the intervention or outcome of this trial.
  7. Digestive system diseases (such as peptic ulcers, gastric bleeding).
  8. Patients with coronary artery disease.
  9. Patients with renal impairment (serum creatinine > 176 µmol/L) and abnormal liver function(alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 2× the upper limit of normal (ULN) or total bilirubin (TBIL) ≥ 1.5×ULN).
  10. Subjects with coagulation dysfunction (prothrombin time or activated partial thromboplastin time is higher than the normal threshold) or patients who are taking oral anticoagulants for other medical reasons and have not stopped it before surgery, such as warfarin or new anticoagulants rivaroxaban or dabigatran.
  11. Patients with a history of allergy to anyone of the study drugs.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
134 participants (estimated)

Study arms

  • Active comparator
    On the contralateral side

    We apply Loxoprofen Sodium Patch on the contralateral side of the incision in patients undergoing laparoscopic surgery 12 hours before surgery.

    Drug: Loxoprofen Sodium Patch on the contralateral side

  • Experimental
    On the incision site

    Apply Loxoprofen Sodium Patch to the incision site of patients undergoing laparoscopic surgery 12 hours before surgery

    Drug: Loxoprofen Sodium Patch on the incision site

Interventions

  • DrugLoxoprofen Sodium Patch on the contralateral side

    Apply Loxoprofen Sodium Patch on the contralateral side of the incision in patients undergoing laparoscopic surgery 12 hours before surgery.

    Also known as: Active Comparator

  • DrugLoxoprofen Sodium Patch on the incision site

    Apply Loxoprofen Sodium Patch on the incision site of patients undergoing laparoscopic surgery 12 hours before surgery

06

What researchers measure

Primary outcomes

  1. Intravenous Morphine Equivalents of Rescue Analgesic Medications Within 48 Hours Postoperatively

    Time frame: The postoperative period 48 hours

Secondary outcomes

  1. Area Under the Curve (AUC) of Numeric Rating Scale at rest (NRSr) Within 0-72 Hours Postoperatively

    scores of 1-3 indicate mild pain, 4-6 denote moderate pain, and 7-10 signify severe pain

    Time frame: Data will be collected at 4、12、24、36 and 72 hours postoperatively

  2. Area under the curve (AUC) of the Numerical Rating Scale during movement (NRSm) within 0-72 hours postoperatively

    The Numeric Rating Scale (NRS) designates 0 as representing no pain and 10 as representing the most severe pain, scores of 1-3 indicate mild pain, 4-6 denote moderate pain, and 7-10 signify severe pain.

    Time frame: Data will be collected at 4、12、24、36 and 72 hours postoperatively

  3. Numeric Rating Scale at rest (NRSr) at 1 week, 1 month, and 3 months postoperatively

    The Numeric Rating Scale (NRS) designates 0 as representing no pain and 10 as representing the most severe pain; scores of 1-3 indicate mild pain, 4-6 denote moderate pain, and 7-10 signify severe pain.

    Time frame: Postoperative day 7, month 1, and month 3.

  4. Patient Satisfaction Scale(PSS)

    Patient Satisfaction Scale(PSS) on a scale ranging from 0 to 10, where 0 denotes "completely dissatisfied" and 10 signifies "extremely satisfied."

    Time frame: Postoperative hours 4、12、24 and 48 hours

  5. Postoperative nausea and vomiting(PONV)

    Time frame: Postoperatively within 48 hours

  6. wound healing score

    The wound healing score is evaluated by independent researchers based on the wound healing score table, which includes three aspects: skin healing, incision infection, and hair growth. The total score is obtained by adding up the three scores. Excellent wound healing: 3 points; Good wound healing is 4-5; Poor wound healing: total score greater than or equal to 6 points.

    Time frame: Postoperative 72hours、1 and 3 months.

  7. postoperatively and patient and observer scar assessment scale

    Postoperatively and patient and observer scar assessment scale: the observer scores the scar based on the distribution of blood vessels around the incision, color, scar thickness, surface roughness, area, and softness. Each score ranges from 1 to 10 points and higher scores indicating more severe scars; The patient evaluates the scar based on whether there is pain or itching, color, softness, thickness, and self-perception. Each score range is also 1-10 points, with 1 point indicating no difference from normal skin and a higher score indicating more severe scars.

    Time frame: Postoperative 72 hours、1 and 3 months

  8. Adverse events

    Such as itching, erythema, contact dermatitis, discomfort in the stomach, elevated ALT (GPT) and elevated AST (GOT)

    Time frame: Within 72 hours postoperatively

07

Study locations

1 of 2 sites recruiting
  • Beijing Tiantan Hospital
    Beijing, Beijing Municipality 100070, China
    Not yet recruiting
  • Beijing Tiantan Hospital
    Beijing, Beijing Municipality 100070, China
    Recruiting
08

References and documents

Publications

  • Fujiki EN, Netto NA, Kraychete DC, Daher MT, Tardini R, Nakamoto A, Lopes DG. Efficacy and safety of loxoprofen sodium topical patch for the treatment of pain in patients with minor acute traumatic limb injuries in Brazil: a randomized, double-blind, noninferiority trial. Pain. 2019 Jul;160(7):1606-1613. doi: 10.1097/j.pain.0000000000001549. PubMed 30839430 ↗
  • Lee IO, Kim SH, Kong MH, Lee MK, Kim NS, Choi YS, Lim SH. Pain after laparoscopic cholecystectomy: the effect and timing of incisional and intraperitoneal bupivacaine. Can J Anaesth. 2001 Jun;48(6):545-50. doi: 10.1007/BF03016830. PubMed 11444448 ↗
  • Bisgaard T, Klarskov B, Kristiansen VB, Callesen T, Schulze S, Kehlet H, Rosenberg J. Multi-regional local anesthetic infiltration during laparoscopic cholecystectomy in patients receiving prophylactic multi-modal analgesia: a randomized, double-blinded, placebo-controlled study. Anesth Analg. 1999 Oct;89(4):1017-24. doi: 10.1097/00000539-199910000-00036. PubMed 10512282 ↗

Individual participant data

Plan to share: Yes

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07591207
Lead sponsor
Beijing Tiantan Hospital
Responsible party
Fang Luo (Director, Department of Day Surgery, Principal, Beijing Tiantan Hospital) — Principal investigator
First posted
May 15, 2026
Start date
Jun 1, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Jun 16, 2026

Study contacts

Fang Luo
Contact
13611326978@163.com
+86 13611326978

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion